Early conversion to belatacept after renal transplantation

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Calcineurin inhibitors pose risks for patients with delayed or slow graft function post-transplant.
• Belatacept offers a non-nephrotoxic immunosuppressive alternative.
• Limited data exist on early belatacept conversion (within 6 months) for these patients.

Purpose of the Study:

• To evaluate the safety and efficacy of early conversion to belatacept in kidney transplant recipients experiencing delayed or slow graft function.
• To assess the impact of conversion timing (≤4 months vs. 4-6 months) on outcomes.
• To analyze graft and patient survival, renal function, and adverse events.

Main Methods:

• Retrospective analysis of 16 kidney transplant recipients converted to belatacept for delayed/poor graft function (eGFR<30 mL/min/1.73 m²).
• Patients were categorized based on conversion timing: ≤4 months and 4-6 months post-transplantation.
• Serum creatinine levels, patient survival, graft survival, and adverse events (rejection, infection, malignancy) were compared pre- and post-conversion.

Main Results:

• Patient survival was 100%, and graft survival was 88% at 12 months post-conversion.
• Mean serum creatinine significantly decreased from 3.9 mg/dL pre-conversion to 1.9 mg/dL at 12 months post-conversion.
• No significant increase in rejection, infection, or malignancy was observed. HIV parameters remained stable.

Conclusions:

• Early conversion to belatacept is a safe and effective strategy for kidney transplant recipients with delayed or slow graft function.
• This approach can lead to significant improvements in renal function and maintain favorable long-term outcomes.
• Belatacept represents a viable non-nephrotoxic option for managing immunosuppression in this patient population.